Drug Development

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Continuous manufacturing and a quality-by-design development approach are a natural fit.

February 28, 2024

Nona Biosciences and Boostimmune will collaborate to develop ADCs against novel targets using Nona’s proprietary platform technology.

February 20, 2024

Webinar Date/Time: Thu, Mar 14, 2024 2:00 PM EDT

February 16, 2024

Webinar Date/Time: Wed, Mar 27, 2024 11:00 AM EDT

February 15, 2024

BioVaxys has acquired the full portfolio of discovery, preclinical, and clinical development-stage assets of the former IMV.

February 12, 2024

Under the new partnership, Samsung Biologics will develop and manufacture an antibody for a LegoChem Biosciences ADC candidate.

February 12, 2024

Webinar Date/Time: Tue, Mar 5, 2024 2:00 PM EST

February 09, 2024

The three non-commercial developers of ATMPs will benefit from enhanced support from the agency.